{
    "Trade/Device Name(s)": [
        "Veri-Q self-testing MGD-1001 Blood Glucose Monitoring System",
        "Veri-Q plus MGD-1001 Blood Glucose Monitoring System"
    ],
    "Submitter Information": "MiCoBioMed Co., Ltd.",
    "510(k) Number": "K123007",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083468"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JJX"
    ],
    "Summary Letter Date": "May 28, 2013",
    "Summary Letter Received Date": "May 30, 2013",
    "Submission Date": "May 27, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Veri-Q self-testing MGD-1001 meter",
        "Veri-Q plus MGD-1001 meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical measurement"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Monitoring System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Lancing Device",
        "Lancet"
    ],
    "Document Summary": "FDA 510(k) summary for Veri-Q self-testing and Veri-Q plus MGD-1001 Blood Glucose Monitoring Systems for quantitative glucose measurement in capillary whole blood.",
    "Indications for Use Summary": "Veri-Q self-testing system is intended for quantitative measurement of glucose in fresh capillary whole blood for home self-testing by single patients; Veri-Q plus system is for multi-patient use in professional healthcare settings, both as aids to monitor diabetes control, not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}